MiNK Therapeutics, Inc.
INKTHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeMiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural. With a market capitalization of $54.7M, it sits in micro-cap territory. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab and balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastroesophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome (ARDS).
Market Cap
$54.7M
Beta
0.47
P/E (TTM)
—
P/E (Fwd)
-4.89
EPS (TTM)
$-2.39
EPS (Fwd)
$-2.19
ROE
—
ROA
-123.8%
Cash
$8.8M
Total Debt
$0
Free CF
-$5.3M
52W Change
-26.3%
Annual Financials
Cash vs Debt
Where INKT stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, INKT finished 15.55% below its 150-day moving average ($11.32) and 15.85% below its 200-day moving average ($11.36). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is INKT overbought or oversold?
At the October 20, 2026 close, INKT's RSI(14) was 17.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
MiNK Therapeutics, Inc. reports $8.8M in cash and $0 in total debt. Free cash flow is running at -$5.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time.
INKT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence MiNK Therapeutics, Inc.'s trajectory.